20/11/14/10/12 Eureka Alerts 1 Global ( Pharmamar ) PharmaMar will present data at the EORTC-NCI-AACR for its drug Yondelis and several... ...http://health.infrosoft.com/index.php?page=news&op=readNews&id=47026&title=PharmaMar-presents-results-at-EORTC-NCI-AACR-to-highlight-a-pipeline-of-targeted-therapies
In patients with newly diagnosed multiple myeloma, the investigational drug ixazomib when taken orally in combination with lenalidomide and... ...http://www.medindia.net/news/a-promising-oral-drug-combo-for-multiple-myeloma-treatment-143876-1.htm
Custom Search Rhizen Pharmaceuticals S.A. to present preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in Multiple Myeloma... ...http://www.bizwireexpress.com/showstoryGNW.php?storyid=51008
NORTH CHICAGO, Ill. , Nov. 14, 2014 /PRNewswire/ --AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in... ...http://in.advfn.com/p.php?pid=nmona&article=64427237
Quarterly Revenue Growth of 32% Year-Over-Year CARLSBAD, Calif., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (Nasdaq:SGNL) (Signal),... ...http://www.bizwireexpress.com/showstoryGNW.php?storyid=50686
Multiple myeloma also called myeloma...